TAFI is a medical term for thrombin-activated fibrinolytic inhibitor. TAFI is a hepatic synthesized single-chain protein with plasma carboxypeptidase-like properties, which acts as a link between coagulation and fibrinolysis and inhibits fibrinolysis. The basic research of TAFI is an important supplement to the classical coagulation and fibrinolysis regulation mechanism; in vivo, it is mainly activated by thrombin, thrombin-regulating protein, fibrinolytic enzyme, heparin, trypsin and other substances, resulting in inhibition of fibrinolytic mechanism and prolongation of thrombolysis time, thus increasing the risk of thrombosis. TAFI is also involved in the regulation of bradykinin, complement and other active substances in vivo. Animal thrombosis models have been treated with TAFI antagonists in combination with thrombolytic agents with good results.